| [1] |
Patel NJ, Deshmukh A, Pant S, et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning[J]. Circulation, 2014, 129(23): 2371-2379.
|
| [2] |
Sun T, Ye M, Lei F, et al. Prevalence and trend of atrial fibrillation and its associated risk factors among the population from nationwide health check-up centers in China, 2012-2017[J]. Front Cardiovasc Med, 2023, 10:1151575.
|
| [3] |
中华医学会老年医学分会心血管学组, 中国老年保健医学研究会老年心血管病分会. 老年心房颤动诊治中国专家共识(2024)[J]. 中华心律失常学杂志, 2024, 28(2):103-124.
|
| [4] |
Lotze U, Liebetrau J, Malsch I, et al. Medical treatment of patients with atrial fibrillation aged over 80 years in daily clinical practice: influence of age and CHADS(2) score[J]. Arch Gerontol Geriatr, 2010, 50(1):36-41.
|
| [5] |
Sankaranarayanan R, Kirkwood G, Dibb K, et al. Comparison of atrial fibrillation in the young versus that in the elderly: a review[J]. Cardiol Res Pract, 2013, 2013:976976.
|
| [6] |
Gourraud JB, Khairy P, Abadir S, et al. Atrial fibrillation in young patients[J]. Expert Rev Cardiovasc Ther, 2018, 16(7):489-500.
|
| [7] |
Shi S, Tang Y, Zhao Q, et al. Prevalence and risk of atrial fibrillation in China: a national cross-sectional epidemiological study[J]. Lancet Reg Health West Pac, 2022, 23:100439.
|
| [8] |
Deshmukh A, Pothineni NV, Patel N, et al. Trends in hospitalizations of young patients with atrial fibrillation: a cause for concern?[J]. Int J Cardiol, 2016, 203:164-165.
|
| [9] |
Pothineni NV K, Voruganti D, Agnihotri K, et al. Safety of atrial fibrillation ablation in the young – a real world analysis[J]. J Atr Fibrillation, 2021, 13(6): 20200489.
|
| [10] |
Cheng S, He J, Han Y, et al. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021[J]. Europace. 2024;26(7):euae195.
|
| [11] |
Goudevenos JA, Vakalis JN, Giogiakas V, et al. An epidemiological study of symptomatic paroxysmal atrial fibrillation in Northwest Greece[J]. Europace, 1999, 1(4):226-233.
|
| [12] |
Djekic D, Lindgren M, Åberg ND, et al. Body mass index in adolescence and long-term risk of early incident atrial fibrillation and subsequent mortality, heart failure, and ischemic stroke[J]. J Am Heart Assoc, 2022, 11(21):e025984.
|
| [13] |
Mattioli AV, Bonatti S, Zennaro M, et al. The relationship between personality, socio-economic factors, acute life stress and the development, spontaneous conversion and recurrences of acute lone atrial fibrillation[J]. Europace, 2005, 7(3):211-220.
|
| [14] |
Mattioli AV, Bonatti S, Zennaro M, et al. Effect of coffee consumption, lifestyle and acute life stress in the development of acute lone atrial fibrillation[J]. J Cardiovasc Med (Hagerstown), 2008, 9(8):794-798.
|
| [15] |
Paludan-Müller C, Vad OB, Stampe NK, et al. Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality[J]. Eur Heart J, 2024, 45(24):2119-2129.
|
| [16] |
van Alebeek ME, Arntz RM, Ekker MS, et al. Risk factors and mechanisms of stroke in young adults: the FUTURE study[J]. J Cereb Blood Flow Metab, 2018, 38(9): 1631-1641.
|
| [17] |
Šaňák D, Hutyra M, Král M, et al. Atrial fibrillation in young ischemic stroke patients: an underestimated cause?[J]. Eur Neurol, 2015, 73(3-4):158-163.
|
| [18] |
Garrido‐Hernández T, Amaya‐Pascasio L, Quesada‐López M, et al. Atrial fibrillation in young stroke patients: associated factors and outcomes in a nationwide analysis[J]. Euro Neurol, 2025, 32(1): e16555.
|
| [19] |
Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J, 2024, 45(36):3314-3414.
|
| [20] |
Putaala J, Yesilot N, Waje-Andreassen U, et al. Demographic and geographic vascular risk factor differences in European young adults with ischemic stroke: the 15 cities young stroke study[J]. Stroke, 2012, 43(10):2624-2630.
|
| [21] |
Lurie A, Wang J, Hinnegan KJ, et al. Prevalence of left atrial thrombus in anticoagulated patients with atrial fibrillation[J]. J Am Coll Cardiol, 2021, 77(23):2875-2886.
|
| [22] |
Chen J, Zhou M, Wang H, et al. Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score[J]. J Thromb Thrombolysis, 2022, 53(2):523-531.
|
| [23] |
Holmgren A, Giang KW, Fedchenko M, et al. Ischemic stroke in patients with congenital heart disease and atrial fibrillation[J]. J Am Heart Assoc, 2024, 13(17):e032813.
|
| [24] |
Hijazi Z, Siegbahn A, Andersson U, et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial[J]. Circulation, 2014, 129(6):625-634.
|
| [25] |
Tanaka S, Hirai T, Inao K, et al. High cardiac troponin I is associated with transesophageal echocardiographic risk of thromboembolism and ischemic stroke events in non-valvular atrial fibrillation patients[J]. Circ J, 2018, 82(6):1699-1704.
|
| [26] |
Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy[J]. Circulation, 2012, 125(13):1605-1616.
|
| [27] |
Hijazi Z, Lindbäck J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation[J]. Eur Heart J, 2016, 37(20):1582-1590.
|
| [28] |
Berg DD, Ruff CT, Jarolim P, et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48[J]. Circulation, 2019, 139(6):760-771.
|
| [29] |
van den Ham HA, Klungel OH, Singer DE, et al. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database[J]. J Am Coll Cardiol, 2015, 66(17):1851-1859.
|
| [30] |
Dalgaard F, Pieper K, Verheugt F, et al. GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study[J]. BMJ Open, 2019, 9(11):e033283.
|
| [31] |
Huang H, Xiong Y, Yao Y, et al. Stroke prediction in elderly patients with atrial fibrillation using machine learning combined clinical and left atrial appendage imaging phenotypic features[J]. BMC Cardiovasc Disord, 2025, 25(1):400.
|
| [32] |
Aggarwal N, Selvendran S, Raphael CE, et al. Atrial fibrillation in the young: a neurologist's nightmare[J]. Neurol Res Int, 2015, 2015:374352.
|
| [33] |
Kirchhof P, Radaideh G, Kim YH, et al. Global prospective safety analysis of rivaroxaban[J]. J Am Coll Cardiol, 2018, 72(2):141-153.
|
| [34] |
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011, 365(11):981-992.
|
| [35] |
Guo X, Du J, Yang Y, et al. Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry[J]. Sci Rep, 2024, 14(1):2778.
|
| [36] |
Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial[J]. Circulation, 2011, 123(21):2363-2372.
|
| [37] |
中国医师协会心血管内科医师分会结构性心脏病学组, 苏州工业园区东方华夏心血管健康研究院. 中国经导管左心耳封堵术临床路径专家共识(2025版)[J/OL]. 中华心脏与心律电子杂志, 2025, 13(1): 1-28.
|
| [38] |
Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial[J]. Lancet, 2009, 374(9689):534-542.
|
| [39] |
Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial[J]. J Am Coll Cardiol, 2014, 64(1):1-12.
|
| [40] |
Kerr C, Boone J, Connolly S, et al. Follow-up of atrial fibrillation: the initial experience of the Canadian registry of atrial fibrillation[J]. Eur Heart J, 1996, 17 (Suppl C):48-51.
|
| [41] |
Wasmer K, Breithardt G, Eckardt L. The young patient with asymptomatic atrial fibrillation: what is the evidence to leave the arrhythmia untreated?[J]. Eur Heart J, 2014, 35(22): 1439-1447.
|
| [42] |
中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 洋地黄类药物临床应用中国专家共识[J]. 中华心血管病杂志, 2019, 47(11): 857-864.
|
| [43] |
Andrade JG, Gin K, Kerr C, et al. How to optimize rate control in clinical atrial fibrillation management[J]. Can J Cardiol, 2013, 29(10):1299-1301.
|
| [44] |
Leng S, Zhao X, Koh AS, et al. Age-related changes in four-dimensional CMR-derived atrioventricular junction velocities and displacements: Implications for the identification of altered annular dynamics for ventricular function assessment[J]. Int J Cardiol Heart Vasc, 2019, 22:6-12.
|
| [45] |
Kaszala K, Ellenbogen KA. Role of cardiac resynchro- nization therapy and atrioventricular junction ablation in patients with permanent atrial fibrillation[J]. Eur Heart J, 2011, 32(19):2344-2346.
|
| [46] |
Curcio A, Scalise R, Indolfi C. Pathophysiology of atrial fibrillation and approach to therapy in subjects less than 60 years old[J]. Int J Mol Sci, 2024, 25(2):758.
|
| [47] |
Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation[J]. N Engl J Med, 2020, 383(14):1305-1316.
|
| [48] |
Dagres N, Lewalter T, Lip GY, et al. Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: the European Heart Rhythm Association survey[J]. Europace, 2013, 15(4):478-481.
|
| [49] |
Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation[J]. N Engl J Med, 2002, 347(23):1825-1833.
|
| [50] |
Van Gelder IC, Haegeli LM, Brandes A, et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation[J]. Europace, 2011, 13(11):1517-1525.
|
| [51] |
Freemantle N, Lafuente-Lafuente C, Mitchell S, et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation[J]. Europace, 2011, 13(3):329-345.
|
| [52] |
Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study[J]. J Am Coll Cardiol, 2006, 48(11):2340-2347.
|
| [53] |
Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study)[J]. Eur Heart J, 2006, 27(2):216-221.
|
| [54] |
Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study[J]. Circulation, 2008, 118(24):2498-2505.
|
| [55] |
Leong-Sit P, Zado E, Callans DJ, et al. Efficacy and risk of atrial fibrillation ablation before 45 years of age[J]. Circ Arrhythm Electrophysiol, 2010, 3(5):452-457.
|
| [56] |
Chun KR, Schmidt B, Kuck KH, et al. Catheter ablation of atrial fibrillation in the young: insights from the German ablation registry[J]. Clin Res Cardiol, 2013, 102(6): 459-468.
|
| [57] |
Saguner AM, Maurer T, Wissner E, et al. Catheter ablation of atrial fibrillation in very young adults: a 5-year follow-up study[J]. Europace, 2018, 20(1):58-64.
|
| [58] |
Ghannam M, Chugh A, Bradley DJ, et al. Clinical characteristics and long-term outcomes of catheter ablation in young adults with atrial fibrillation[J]. J Interv Card Electrophysiol, 2022, 64(2): 311-319.
|
| [59] |
Johnson BM, Wazni OM, Farwati M, et al. Atrial fibrillation ablation in young adults: measuring quality of life using patient-reported outcomes over 5 years[J]. Circ Arrhythm Electrophysiol, 2023, 16(6):e011565.
|
| [60] |
Ahn HJ, Cha MJ, Lee E, et al. The higher recurrence rate after catheter ablation in younger patients with atrial fibrillation suggesting different pathophysiology[J]. J Interv Card Electrophysiol, 2023, 66(7):1609-1619.
|
| [61] |
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a Report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2024, 83(1):109-279.
|
| [62] |
中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6) : 572-618.
|
| [63] |
Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study[J]. Lancet, 2015, 386(9989):154-162.
|
| [64] |
Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE consortium (Biomarker for Cardiovascular Risk Assessment in Europe)[J]. Circulation, 2017, 136(17):1588-1597.
|
| [65] |
Lu B, Huang B, Wang Y, et al. Mitochondrial calcium homeostasis mediated by estradiol contributes to atrial fibrillation protection[J]. Biochem Biophys Res Commun, 2025, 772:152050.
|
| [66] |
Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. a population-based study over three decades[J]. N Engl J Med, 1987, 317(11):669-674.
|
| [67] |
Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is a genetically heterogeneous disorder[J]. J Am Coll Cardiol, 2003, 41(12):2185-2192.
|
| [68] |
Olesen MS, Andreasen L, Jabbari J, et al. Very early-onset lone atrial fibrillation patients have a high prevalence of rare variants in genes previously associated with atrial fibrillation[J]. Heart Rhythm, 2014, 11(2):246-251.
|
| [69] |
Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms[J]. Circ Res, 2014, 114(9):1453-1468.
|
| [70] |
Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial[J]. JAMA, 2013, 310(19):2050-2060.
|
| [71] |
Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation[J]. J Am Coll Cardiol, 2007, 49(5):565-571.
|
| [72] |
Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation[J]. Circulation, 2003, 107(20):2589-2594.
|
| [73] |
Hunt TE, Traaen GM, Aakerøy L, et al. Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial[J]. Heart Rhythm, 2022, 19(9): 1433-1441.
|
| [74] |
Ofman P, Khawaja O, Rahilly-Tierney CR, et al. Regular physical activity and risk of atrial fibrillation: a systematic review and meta-analysis[J]. Circ Arrhythm Electrophysiol, 2013, 6(2):252-256.
|
| [75] |
Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? a systematic review and meta-analysis[J]. Europace, 2009, 11(9): 1156-1159.
|
| [76] |
Garnvik LE, Malmo V, Janszky I, et al. Physical activity, cardiorespiratory fitness, and cardiovascular outcomes in individuals with atrial fibrillation: the HUNT study[J]. Eur Heart J, 2020, 41(15):1467-1475.
|
| [77] |
Csengeri D, Sprünker NA, Di Castelnuovo A, et al. Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes[J]. Eur Heart J, 2021, 42(12):1170-1177.
|
| [78] |
Lee SR, Choi EK, Jung JH, et al. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study[J]. Eur Heart J, 2021, 42(46):4759-4768.
|
| [79] |
Voskoboinik A, Kalman JM, De Silva A, et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation[J]. N Engl J Med, 2020, 382(1):20-28.
|
| [80] |
Xue X, Hu J, Xiang D, et al. Hourly air pollution exposure and the onset of symptomatic arrhythmia: an individual-level case-crossover study in 322 Chinese cities[J]. CMAJ, 2023, 195(17):E601-E611.
|
| [81] |
Fu Y, He W, Ma J, et al. Relationship between psychological factors and atrial fibrillation: a meta-analysis and systematic review[J]. Medicine (Baltimore), 2020, 99(16):e19615.
|
| [82] |
Soliman EZ, Rahman AF, Zhang ZM, et al. Effect of intensive blood pressure lowering on the risk of atrial fibrillation[J]. Hypertension, 2020, 75(6):1491-1496.
|
| [83] |
Galzerano D, Di Michele S, Paolisso G, et al. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hyper- tensive patients[J]. J Renin Angiotensin Aldosterone Syst, 2012, 13(4):496-503.
|
| [84] |
Basic C, Rosengren A, Alehagen U, et al. Young patients with heart failure: clinical characteristics and outcomes. data from the Swedish heart failure, national patient, population and cause of death registers[J]. Eur J Heart Fail, 2020, 22(7):1125-1132.
|
| [85] |
Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial[J]. Circulation, 2016, 133(17): 1637-1644.
|
| [86] |
Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure[J]. N Engl J Med, 2018, 378(5):417-427.
|
| [87] |
Kany S, Jurgens SJ, Rämö JT, et al. Genetic testing in early-onset atrial fibrillation[J]. Eur Heart J, 2024, 45(34):3111-3123.
|
| [88] |
Mizia-Stec K, Caforio A, Charron P, et al. Atrial fibrillation, anticoagulation management and risk of stroke in the cardiomyopathy/myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology[J]. ESC Heart Fail, 2020, 7(6):3601-3609.
|
| [89] |
Mandalenakis Z, Rosengren A, Lappas G, et al. Atrial fibrillation burden in young patients with congenital heart disease[J]. Circulation, 2018, 137(9): 928-937.
|
| [90] |
Bouchardy J, Therrien J, Pilote L, et al. Atrial arrhythmias in adults with congenital heart disease[J]. Circulation, 2009, 120(17): 1679-1686.
|
| [91] |
Echouffo-Tcheugui JB, Shrader P, Thomas L, et al. Care Patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF registry[J]. J Am Coll Cardiol, 2017, 70(11):1325-1335.
|
| [92] |
Huxley RR, Filion KB, Konety S, et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation[J]. Am J Cardiol, 2011, 108(1):56-62.
|
| [93] |
Guo S, Huang Y, Liu X, et al. Association of type 1 diabetes mellitus and risk of atrial fibrillation: systematic review and meta-analysis[J]. Diabetes Res Clin Pract, 2023, 199:110629.
|
| [94] |
Li D, Liu Y, Hidru TH, et al. Protective effects of sodium-glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: a systematic review and meta- analysis of randomized placebo-controlled trials[J]. Front Endocrinol (Lausanne), 2021, 12:619586.
|
| [95] |
Ahmad M, Reddy S, Barkhane Z, et al. Hyperthyroidism and the risk of cardiac arrhythmias: a narrative review[J]. Cureus, 2022, 14(4):e24378.
|
| [96] |
Reddy V, Taha W, Kundumadam S, et al. Atrial fibrillation and hyperthyroidism: a literature review[J]. Indian Heart J, 2017, 69(4):545-550.
|
| [97] |
Guo Y, Wang H, Zhang H, et al. Mobile photo- plethysmographic technology to detect atrial fibrillation[J]. J Am Coll Cardiol, 2019, 74(19):2365-2375.
|
| [98] |
Krivoshei L, Weber S, Burkard T, et al. Smart detection of atrial fibrillation[J]. Europace, 2017, 19(5):753-757.
|
| [99] |
Lopez Perales CR, Van Spall H, Maeda S, et al. Mobile health applications for the detection of atrial fibrillation: a systematic review[J]. Europace, 2021, 23(1):11-28.
|
| [100] |
Segev A, Maor E, Goldenfeld M, et al. Atrial fibrillation in young hospitalized patients: clinical characteristics, predictors of new onset, and outcomes[J]. J Cardiol, 2023, 82(5):408-413.
|